Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

73.90USD
26 Apr 2018
Change (% chg)

$0.65 (+0.89%)
Prev Close
$73.25
Open
$73.28
Day's High
$74.32
Day's Low
$72.09
Volume
6,341,076
Avg. Vol
7,882,519
52-wk High
$89.54
52-wk Low
$63.76

Chart for

About

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS),... (more)

Overall

Beta: 1.21
Market Cap(Mil.): $94,815.98
Shares Outstanding(Mil.): 1,303.85
Dividend: 0.57
Yield (%): 3.11

Financials

  GILD.O Industry Sector
P/E (TTM): 9.53 173.69 32.21
EPS (TTM): 7.69 -- --
ROI: 19.15 -0.70 13.05
ROE: 51.46 -2.69 14.90

U.S. court upholds dismissal of $200 million Merck verdict against Gilead

A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc.

Apr 25 2018

UPDATE 1-U.S. court upholds dismissal of $200 mln Merck verdict against Gilead

April 25 A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc.

Apr 25 2018

BRIEF-Galapagos Q1 Operating Loss Widens To 32.0 Million Euros

* Q1 REVENUE EUR 44.8 MILLION VERSUS EUR 39.9 MILLION YEAR AGO

Apr 25 2018

REFILE-U.S. court upholds dismissal of $200 million Merck verdict against Gilead

April 25 A U.S. appeals court on Wednesday affirmed a ruling that pharmaceutical company Merck & Co dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict it won against rival Gilead Sciences Inc.

Apr 25 2018

Nonprofit sues over NIH licensing of cancer tech to Gilead

A nonprofit group is suing to challenge the National Institutes of Health's plan to grant a license on taxpayer-funded cancer treatment technology to a Gilead Sciences Inc unit, arguing the decision ignored the public's interest in affordable drugs.

Apr 20 2018

FDA staff raises safety concerns over Lilly/Incyte arthritis drug

An experimental rheumatoid arthritis drug developed by Eli Lilly and Co and Incyte Corp poses serious risks of deadly blood clots at higher doses, U.S. Food and Drug Administration staff said on Thursday, the latest setback to a treatment regulators declined to approve last year.

Apr 19 2018

UPDATE 2-FDA staff raises safety concerns over Lilly/Incyte arthritis drug

* Limited data on 2 mg dose complicates risk/benefit analysis

Apr 19 2018

BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite, A Gilead Co

* ASTELLAS ANNOUNCES SALE OF CERTAIN AGENSYS RESEARCH FACILITIES TO KITE, A GILEAD COMPANY

Apr 18 2018

Supreme Court seeks DOJ view on Gilead whistleblower case

The U.S. Supreme Court on Monday asked the solicitor general to weigh in on whether to grant review in a case involving Gilead Sciences Inc to consider what constitutes a material misrepresentation by companies submitting claims to the government for payment.

Apr 16 2018

GlaxoSmithKline prescribes commercial reboot for pharma division

LONDON In January, GlaxoSmithKline's new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent.

Mar 21 2018

Competitors

Earnings vs. Estimates